Terug
46
41
25
Dagbereik
€ 18,41
€ 18,90
52-Weeksbereik
€ 8,62
€ 20,78
Volume
400
50D / 200D Gem.
€ 17,91
/
€ 13,07
Vorige Slotkoers
€ 18,41
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (633 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 18,5 | 0,2 |
| P/B | 4,8 | 2,8 |
| ROE % | 38,8 | 3,8 |
| Net Margin % | 5,8 | 3,9 |
| Rev Growth 5Y % | 9,2 | 10,0 |
| D/E | 0,9 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2028 |
€ 1,73
€ 1,65 – € 1,83
|
2,50B | 1 |
| FY2027 |
€ 1,49
€ 1,42 – € 1,57
|
2,39B | 1 |
| FY2026 |
€ 1,27
€ 1,21 – € 1,34
|
2,20B | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-26 | € 0,26 | € 0,21 | -21,3% |
| 2025-08-06 | € 0,13 | € 0,27 | +104,8% |
| 2025-05-06 | € 0,11 | € 0,12 | +8,6% |
| 2025-02-27 | € 0,12 | € 0,15 | +21,5% |
| 2024-11-12 | N/A | € 0,14 | — |
| 2024-08-12 | N/A | € 0,20 | — |
| 2024-05-15 | N/A | € 0,10 | — |
| 2024-03-08 | N/A | € 0,07 | — |
Dividend History
7 yr streakYield
0,02%
Payout Ratio
0,43%
Growth (3Y)
-0,85%
Growth (5Y)
-0,01%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 31, 2026 | Apr 15, 2026 | € 0,03 | 1,94% |
| Feb 27, 2026 | Mar 16, 2026 | € 0,03 | 1,84% |
| Jan 30, 2026 | Feb 16, 2026 | € 0,03 | 2,10% |
| Dec 31, 2025 | Jan 15, 2026 | € 0,03 | 2,30% |
| Nov 28, 2025 | Dec 15, 2025 | € 0,03 | 2,43% |
| Oct 31, 2025 | Nov 17, 2025 | € 0,03 | 3,07% |
| Sep 29, 2025 | Oct 15, 2025 | € 0,03 | 3,24% |
| Aug 29, 2025 | Sep 15, 2025 | € 0,03 | 3,70% |
| Jul 31, 2025 | Aug 15, 2025 | € 0,03 | 3,93% |
| Jun 30, 2025 | Jul 15, 2025 | € 0,03 | 3,37% |
| May 30, 2025 | Jun 16, 2025 | € 0,03 | 3,31% |
| Apr 30, 2025 | May 15, 2025 | € 0,03 | 3,52% |
| Mar 31, 2025 | Apr 15, 2025 | € 0,03 | 3,78% |
| Feb 28, 2025 | Mar 17, 2025 | € 0,03 | 3,95% |
| Jan 31, 2025 | Feb 14, 2025 | € 0,03 | 4,76% |
| Dec 31, 2024 | Jan 15, 2025 | € 0,03 | 4,81% |
| Nov 29, 2024 | Dec 16, 2024 | € 0,03 | 4,66% |
| Oct 31, 2024 | Nov 15, 2024 | € 0,03 | 5,30% |
| Sep 27, 2024 | Oct 15, 2024 | € 0,03 | 5,12% |
| Aug 30, 2024 | Sep 16, 2024 | € 0,03 | 5,50% |
Belangrijkste Punten
Revenue grew 9,19% annually over 5 years — modest growth
Earnings grew 28,41% over the past year
ROE of 38,83% indicates high profitability
Generating 63,35M in free cash flow
PEG of 0,83 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3,96%
Groei
Revenue Growth (5Y)
9,19%
Revenue (1Y)13,15%
Earnings (1Y)28,41%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
38,83%
ROIC14,49%
Net Margin5,82%
Op. Margin8,33%
Veiligheid
Debt / Equity
0,92
Current Ratio1,37
Interest Coverage7,20
Waardering
P/E Ratio
18,49
Forward P/E14,49
P/B Ratio4,79
EV/EBITDA12,87
Dividend Yield0,02%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 13,15% | Revenue Growth (3Y) | 12,75% |
| Earnings Growth (1Y) | 28,41% | Earnings Growth (3Y) | 68,58% |
| Revenue Growth (5Y) | 9,19% | Earnings Growth (5Y) | 70,22% |
| Profitability | |||
| Revenue (TTM) | 1,66B | Net Income (TTM) | 96,58M |
| ROE | 38,83% | ROA | 9,06% |
| Gross Margin | 12,02% | Operating Margin | 8,33% |
| Net Margin | 5,82% | Free Cash Flow (TTM) | 63,35M |
| ROIC | 14,49% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,92 | Current Ratio | 1,37 |
| Interest Coverage | 7,20 | ||
| Dividends | |||
| Dividend Yield | 0,02% | Payout Ratio | 0,43% |
| Dividend Growth (3Y) | -0,85% | Dividend Growth (5Y) | -0,01% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 18,49 | Forward P/E | 14,49 |
| P/B Ratio | 4,79 | P/S Ratio | 1,08 |
| PEG Ratio | 0,83 | Forward PEG | N/A |
| EV/EBITDA | 12,87 | Fwd EV/EBITDA | 10,31 |
| Forward P/S | 0,81 | Fwd Earnings Yield | 6,90% |
| FCF Yield | 3,55% | ||
| Market Cap | 1,79B | Enterprise Value | 1,78B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,66B | 1,47B | 1,30B | 1,22B | 1,17B |
| Net Income | 96,58M | 75,21M | 33,98M | 69,55M | 11,50M |
| EPS (Diluted) | 1,11 | 0,86 | 0,40 | -0,05 | 0,11 |
| Gross Profit | 199,43M | 1,47B | 167,62M | 76,83M | 115,61M |
| Operating Income | 138,25M | 111,21M | 111,79M | 20,99M | 63,18M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,07B | 719,79M | 672,73M | 781,58M | 900,32M |
| Total Liabilities | 692,58M | 595,44M | 584,81M | 680,88M | 798,40M |
| Shareholders' Equity | 373,07M | 124,35M | 87,92M | 100,70M | 101,92M |
| Total Debt | 342,65M | 292,49M | 334,52M | 383,97M | 536,85M |
| Cash & Equivalents | 348,90M | 121,85M | 75,18M | 167,28M | 104,63M |
| Current Assets | 451,57M | 243,70M | 187,14M | 258,04M | 224,92M |
| Current Liabilities | 329,91M | 292,88M | 226,39M | 274,99M | 281,91M |
Strategiescores
This stock passed the criteria for 3 strategies
Score = fit strength (0–100)
Rank = position among all matches
Growth + Value
Growth at a Reasonable Price (Peter Lynch)
#211 of 330
Custom
Balanced Risk
#106 of 151
Custom
Lower Risk
#134 of 139
Recente Activiteit
Ingestapt
Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026
Ingestapt
Balanced Risk
Mar 24, 2026
Ingestapt
Lower Risk
Mar 24, 2026